<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02596230</url>
  </required_header>
  <id_info>
    <org_study_id>1160.188</org_study_id>
    <nct_id>NCT02596230</nct_id>
  </id_info>
  <brief_title>RE-COVERY DVT/PE: Global Study on Treatment Secondary Prevention of Acute Venous Thromboembolism</brief_title>
  <official_title>Characterization of Patients Following Acute Venous Thromboembolism (VTE) and Safety and Effectiveness of Dabigatran Etexilate (DE) in the Treatment and Secondary Prevention of Acute Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) in Comparison to Vitamin K Antagonist (VKA) in Routine Clinical Practice - RE-COVERY DVT/PE</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      RE-COVERY is a large, multi-national, multi-center observational study based on new data
      collection. The study will enroll and characterize patients within 30 days of being diagnosed
      with an acute DVT and/or PE. The study has two main objectives. Objective 1 will characterize
      the DVT / PE patient population. All patients with a DVT and/or PE will be enrolled for
      cross-sectional characterization of the VTE patient population. Objective 2 will compare the
      safety and effectiveness of dabigatran etexilate regimens for treatment of VTE in comparison
      to VKA regimens. Patients treated with dabigatran etexilate or VKA will be followed up for
      the occurrence of outcome events for up to one year.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 5, 2015</start_date>
  <completion_date type="Actual">March 31, 2019</completion_date>
  <primary_completion_date type="Actual">March 31, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Objective 1: Age</measure>
    <time_frame>Baseline collected within 14 days but not more than 6 months after diagnosis of acute deep vein thrombosis (DVT) and/or pulmonary embolism (PE).</time_frame>
    <description>Age in years of eligible patients collected for Objective 1 during baseline at the time of index event. Aim of Objective 1 was to characterize the Venous Thromboembolism (VTE) patient population including the initial acute event phase, i.e. all patients regardless of treatment. Patients who enrolled in Objective 1 and were treated with VKA or dabigatran were also eligible for Objective 2. The aim of objective 2 was to analyze the safety and effectiveness of dabigatran regimens in the treatment of DVT and PE over 1 year of follow-up in comparison to a VKA regimen.
The arm presented in this endpoint was separated into three arms in the participant flow tables (&quot;Not assigned to Dabigatran etexilate or Vitamin K antagonist&quot;,&quot;Dabigatran etexilate (1)&quot; and &quot;Vitamin K antagonist (1)&quot;) in order to distinguish patients participating in both objectives from patients only in objective 2.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective 1: Sex</measure>
    <time_frame>Baseline collected within 14 days but not more than 6 months after diagnosis of acute deep vein thrombosis (DVT) and/or pulmonary embolism (PE).</time_frame>
    <description>Sex of eligible patients collected for Objective 1 during baseline at the time of index event. Aim of Objective 1 was to characterize the Venous Thromboembolism (VTE) patient population including the initial acute event phase, i.e. all patients regardless of treatment. Patients who enrolled in Objective 1 and were treated with VKA or dabigatran were also eligible for Objective 2. The aim of objective 2 was to analyze the safety and effectiveness of dabigatran regimens in the treatment of DVT and PE over 1 year of follow-up in comparison to a VKA regimen.
The arm presented in this endpoint was separated into three arms in the participant flow tables (&quot;Not assigned to Dabigatran etexilate or Vitamin K antagonist&quot;,&quot;Dabigatran etexilate (1)&quot; and &quot;Vitamin K antagonist (1)&quot;) in order to distinguish patients participating in both objectives from patients only in objective 2.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective 1: Index Event</measure>
    <time_frame>Baseline collected within 14 days but not more than 6 months after diagnosis of acute deep vein thrombosis (DVT) and/or pulmonary embolism (PE).</time_frame>
    <description>Type of index event (e.g., DVT or PE or DVT and PE) diagnosed at the time of acute Venous Thromboembolism (VTE) event of eligible patients collected for Objective 1 during baseline at the time of index event. Aim of Objective 1 was to characterize the Venous Thromboembolism (VTE) patient population including the initial acute event phase, i.e. all patients regardless of treatment. Patients who enrolled in Objective 1 and were treated with VKA or dabigatran were also eligible for Objective 2. The aim of objective 2 was to analyze the safety and effectiveness of dabigatran regimens in the treatment of DVT and PE over 1 year of follow-up in comparison to a VKA regimen.
The arm presented in this endpoint was separated into three arms in the participant flow tables (&quot;Not assigned to Dabigatran etexilate or Vitamin K antagonist&quot;,&quot;Dabigatran etexilate (1)&quot; and &quot;Vitamin K antagonist (1)&quot;) in order to distinguish patients participating in both objectives from patients only in objective 2.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective 1: Anticoagulant Treatment</measure>
    <time_frame>Baseline collected within 14 days but not more than 6 months after diagnosis of acute deep vein thrombosis (DVT) and/or pulmonary embolism (PE).</time_frame>
    <description>Type of treatment received following acute Venous Thromboembolism (VTE) event of eligible patients collected for Objective 1 during baseline at the time of index event. Aim of Objective 1 was to characterize the Venous Thromboembolism (VTE) patient population including the initial acute event phase, i.e. all patients regardless of treatment. Patients who enrolled in Objective 1 and were treated with VKA or dabigatran were also eligible for Objective 2. The aim of objective 2 was to analyze the safety and effectiveness of dabigatran regimens in the treatment of DVT and PE over 1 year of follow-up in comparison to a VKA regimen.
The arm presented in this endpoint was separated into three arms in the participant flow tables (&quot;Not assigned to Dabigatran etexilate or Vitamin K antagonist&quot;,&quot;Dabigatran etexilate (1)&quot; and &quot;Vitamin K antagonist (1)&quot;) in order to distinguish patients participating in both objectives from patients only in objective 2.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective 2: Incidence Rate of ISTH (International Society on Thrombosis and Haemostasis) Major Bleeding and CRNMB (Clinically Relevant Non Major Bleeding) Per 100 Patient-years (Pt-yrs)</measure>
    <time_frame>12 months following acute deep vein thrombosis (DVT) and/or pulmonary embolism (PE).</time_frame>
    <description>Incidence rate of ISTH (International Society on Thrombosis and Haemostasis) major bleeding and CRNMB (clinically relevant non major bleeding) per 100 patient-years (1/(100*patient-years)). Each patient in the two treatment groups was weighted proportionally to the probability of that patient being assigned to the opposite treatment group, conditional on relevant observed baseline variables. The propensity scores were estimated using the multivariable logistic regression model.
For the restricted patient set, as a sensitivity analysis, the calculation of incidence rates and cumulative risks was performed without censoring at permanent discontinuation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective 2: Symptomatic Recurrent VTE (Venous Thromboembolism) Including VTE Related Mortality</measure>
    <time_frame>12 months following acute deep vein thrombosis (DVT) and/or pulmonary embolism (PE).</time_frame>
    <description>Incidence rate of Symptomatic Recurrent VTE (Venous Thromboembolism) including VTE related mortality per 100 patient-years (1/(100*patient-years)). Each patient in the two treatment groups was weighted proportionally to the probability of that patient being assigned to the opposite treatment group, conditional on relevant observed baseline variables. The propensity scores were estimated using the multivariable logistic regression model.
For the restricted patient set, as a sensitivity analysis, the calculation of incidence rates and cumulative risks was performed without censoring at permanent discontinuation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective 2: Incidence Rate of Recurrent DVT and/or PE</measure>
    <time_frame>12 months following acute deep vein thrombosis (DVT) and/or pulmonary embolism (PE).</time_frame>
    <description>Incidence rate of Recurrent Deep Vein Thrombosis (DVT) and/or Pulmonary Embolism (PE) per 100 patient-years (1/(100*patient-years)). Each patient in the two treatment groups was weighted proportionally to the probability of that patient being assigned to the opposite treatment group, conditional on relevant observed baseline variables. The propensity scores were estimated using the multivariable logistic regression model.
For the restricted patient set, as a sensitivity analysis, the calculation of incidence rates and cumulative risks was performed without censoring at permanent discontinuation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective 2: Incidence Rate of VTE-related Mortality</measure>
    <time_frame>12 months following acute deep vein thrombosis (DVT) and/or pulmonary embolism (PE).</time_frame>
    <description>Incidence rate of VTE-related Mortality per 100 patient-years (1/(100*patient-years)). Each patient in the two treatment groups was weighted proportionally to the probability of that patient being assigned to the opposite treatment group, conditional on relevant observed baseline variables. The propensity scores were estimated using the multivariable logistic regression model.
For the restricted patient set, as a sensitivity analysis, the calculation of incidence rates and cumulative risks was performed without censoring at permanent discontinuation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective 2: Incidence Rate of All-cause Mortality</measure>
    <time_frame>12 months following acute deep vein thrombosis (DVT) and/or pulmonary embolism (PE).</time_frame>
    <description>Incidence rate of all-cause mortality per 100 patient-years (1/(100*patient-years)). Each patient in the two treatment groups was weighted proportionally to the probability of that patient being assigned to the opposite treatment group, conditional on relevant observed baseline variables. The propensity scores were estimated using the multivariable logistic regression model.
For the restricted patient set, as a sensitivity analysis, the calculation of incidence rates and cumulative risks was performed without censoring at permanent discontinuation.</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">7797</enrollment>
  <condition>Venous Thromboembolism</condition>
  <arm_group>
    <arm_group_label>Patients with acute VTE</arm_group_label>
    <description>Patients will be enrolled for cross sectional characterization of baseline characteristics</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dabigatran</arm_group_label>
    <description>Patients treated with dabigatran for acute VTE will be followed for one year</description>
  </arm_group>
  <arm_group>
    <arm_group_label>vitamin K antagonist</arm_group_label>
    <description>Patients treated with VKA for acute VTE will be followed for one year</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with acute venous thromboembolism
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Written informed consent provided by the patient in accordance with local regulations

          2. Diagnosis of an acute DVT and/or PE (For objective 1, assessment of patient for study
             participation should be done ideally within 14 days but not more than 6 months after
             diagnosis of the acute VTE. For Objective 2, patient assessment should occur ideally
             within 14 days but not more than 30 days from diagnosis)

          3. Age &gt;= 18 years

          4. For Objective 2, the planned anticoagulation therapy should be for at least 3 months

          5. For Objective 2, dabigatran and vitamin K antagonist patients should be available for
             follow-up data collection

        Exclusion criteria:

          1. Need for anticoagulation therapy for conditions other than venous thromboembolism
             (VTE)

          2. Current participation in a clinical trial for VTE indication or current use of an
             unapproved drug
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cardiovascular Innovation and Research Center</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90813</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Health and Life Research Institute, LLC</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33155</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Med-Care Research</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33165</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pines Care Research Center</name>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <zip>33026</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tampa General Hospital</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ellipsis Group</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wellstar Cardiovascular Medicine</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fox Valley Clinical Research Center, LLC</name>
      <address>
        <city>Aurora</city>
        <state>Illinois</state>
        <zip>60504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Genesys Regional Medical Center</name>
      <address>
        <city>Grand Blanc</city>
        <state>Michigan</state>
        <zip>48439</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Of Mississippi Medical Center</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vidant Multispecialty Clnc Kinston</name>
      <address>
        <city>Kinston</city>
        <state>North Carolina</state>
        <zip>28501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanford Cardiology</name>
      <address>
        <city>Sanford</city>
        <state>North Carolina</state>
        <zip>27330</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lycoming Internal Medicine, Inc</name>
      <address>
        <city>Jersey Shore</city>
        <state>Pennsylvania</state>
        <zip>17740</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Associates of Jackson</name>
      <address>
        <city>Jackson</city>
        <state>Tennessee</state>
        <zip>38301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University Of Texas at Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiology Center of Houston, PA</name>
      <address>
        <city>Katy</city>
        <state>Texas</state>
        <zip>77450</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardio Voyage</name>
      <address>
        <city>McKinney</city>
        <state>Texas</state>
        <zip>75071</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Waukesha Heart Institute</name>
      <address>
        <city>Waukesha</city>
        <state>Wisconsin</state>
        <zip>53188</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Austral</name>
      <address>
        <city>Buenos Aires</city>
        <zip>B1629AHJ</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Aleman</name>
      <address>
        <city>Caba</city>
        <zip>1118</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Italiano</name>
      <address>
        <city>Caba</city>
        <zip>1181</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ICBA</name>
      <address>
        <city>Caba</city>
        <zip>1428</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Juncal</name>
      <address>
        <city>Temperley</city>
        <zip>1814</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LKH Feldkirch</name>
      <address>
        <city>Feldkirch</city>
        <zip>6807</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LKH-Univ. Hospital Graz</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of Innsbruck</name>
      <address>
        <city>Innsbruck</city>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ULB Hopital Erasme</name>
      <address>
        <city>Bruxelles</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>C.H.U. de Charleroi</name>
      <address>
        <city>Charleroi</city>
        <zip>6000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H.-Hartziekenhuis</name>
      <address>
        <city>Lier</city>
        <zip>2500</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Liège</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Vera Cruz</name>
      <address>
        <city>Belo Horizonte</city>
        <zip>30140-092</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Faculdade de Ciencias Medicas da UNICAMP</name>
      <address>
        <city>Campinas</city>
        <zip>13083970</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital das Clinicas da Faculdade de Medicina - FMUSP</name>
      <address>
        <city>São Paulo</city>
        <zip>05403-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMHAT St. George</name>
      <address>
        <city>Plovdiv</city>
        <zip>4014</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Heart Hospital, Sofia</name>
      <address>
        <city>Sofia</city>
        <zip>1309</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MHAT 'Tokuda Hospital Sofia', EAD</name>
      <address>
        <city>Sofia</city>
        <zip>1407</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Trakia Park</name>
      <address>
        <city>Stara Zagora</city>
        <zip>6004</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hamilton General Hospital</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8L 2X2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Juravinski Hospital - Hamilton Health Sciences</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V 1C3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SMOLAM</name>
      <address>
        <city>Santiago</city>
        <zip>7500922</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundacion Cardiomet CEQUIN</name>
      <address>
        <city>Armenia</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unidad de Investigaciones Clínicas</name>
      <address>
        <city>Cali</city>
        <zip>760032</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Investigaciones Clinicas S.A.S</name>
      <address>
        <city>Cali</city>
        <zip>760036</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Diagnostico Cardilogico</name>
      <address>
        <city>Cartagena</city>
        <zip>13001</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asociacion IPS Medicos Internistas de Caldas</name>
      <address>
        <city>Manizales</city>
        <zip>170004</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Promotora Medica Las Americas SA</name>
      <address>
        <city>Medellin</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rehabilitacni nemocnice Beroun</name>
      <address>
        <city>Beroun</city>
        <zip>266 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diagangio s.r.o.</name>
      <address>
        <city>Brno</city>
        <zip>61200</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Brno</name>
      <address>
        <city>Brno</city>
        <zip>639 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nemocnice Milosrdnych bratri</name>
      <address>
        <city>Brno</city>
        <zip>63900</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice u sv. Anny v Brne</name>
      <address>
        <city>Brno</city>
        <zip>656 91</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CTC Hodonin s.r.o.</name>
      <address>
        <city>Hodonin</city>
        <zip>695 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MUDr. Ladislav Busak</name>
      <address>
        <city>Louny</city>
        <zip>440 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MUDr. Stanislav Bulir</name>
      <address>
        <city>Mlada Boleslav</city>
        <zip>293 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nemocnice Náchod</name>
      <address>
        <city>Nachod</city>
        <zip>547 69</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MUDr. Dalibor Musil</name>
      <address>
        <city>Olomouc</city>
        <zip>779 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Plzen</name>
      <address>
        <city>Plzen</city>
        <zip>305 99</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vseobecna fakultni nemocnice V Praze</name>
      <address>
        <city>Praha 2</city>
        <zip>128 08</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute for Clinical and Experimental Medicine</name>
      <address>
        <city>Praha 4</city>
        <zip>140 21</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Ashraf ElGhandour Private Clinic</name>
      <address>
        <city>Alexandria</city>
        <zip>21131</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Clinic Dr. Mervat Mattar</name>
      <address>
        <city>Cairo</city>
        <zip>11322</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Clinic Mohamed Moussa</name>
      <address>
        <city>Cairo</city>
        <zip>11341</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Clinic - Dr. Shawky</name>
      <address>
        <city>Cairo</city>
        <zip>12345</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Clinic - Dr. Ahmed Hassouna</name>
      <address>
        <city>Kalyoub</city>
        <zip>13632</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Franziskus-Krankenhaus, Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>10787</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Städtisches Klinikum Dresden</name>
      <address>
        <city>Dresden</city>
        <zip>01067</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis für Gefäßmedizin</name>
      <address>
        <city>Goerlitz</city>
        <zip>02827</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Greifswald</name>
      <address>
        <city>Greifswald</city>
        <zip>17475</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Alexandroupolis</name>
      <address>
        <city>Alexandroupolis</city>
        <zip>68100</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;Laiko&quot; Hospital, 1st Vascular Surgery Clinic of UOA</name>
      <address>
        <city>Athens</city>
        <zip>11527</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Athens Hospital of Chest Diseases &quot;Sotiria&quot;</name>
      <address>
        <city>Athens</city>
        <zip>11527</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gen. Hosp. of Chest Diseases &quot;Sotiria&quot;, 3rd Internal Med. Cl</name>
      <address>
        <city>Athens</city>
        <zip>11527</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University General Hospital Attikon</name>
      <address>
        <city>Athens</city>
        <zip>124 62</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. Gen. Hosp. of Ioannina</name>
      <address>
        <city>Ioannina</city>
        <zip>45 500</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General University Hospital of Larissa</name>
      <address>
        <city>Larissa</city>
        <zip>41110</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Hospital of Athens &quot;G. Gennimatas&quot;</name>
      <address>
        <city>Thessaloniki</city>
        <zip>54635</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University General Hospital of Thessaloniki AHEPA</name>
      <address>
        <city>Thessaloniki</city>
        <zip>54636</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Kenessey Albert Kórház-Rendelõintézet, Balassagyarmat</name>
      <address>
        <city>Balassagyarmat</city>
        <zip>2660</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Istvan Hospital, Budapest</name>
      <address>
        <city>Budapest</city>
        <zip>1096</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jahn Ferenc Del-Pest Hospital</name>
      <address>
        <city>Budapest</city>
        <zip>1204</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Debrecen Hospital</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pest Megyei Flor Ferenc Hospital</name>
      <address>
        <city>Kistarcsa</city>
        <zip>2143</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dorottya Kanizsai Hospital</name>
      <address>
        <city>Nagykanizsa</city>
        <zip>8800</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pecsi Tudomanyegyetem</name>
      <address>
        <city>Pecs</city>
        <zip>7624</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Csongrad Country Dr Bugyi Istvan Hosp.</name>
      <address>
        <city>Szentes</city>
        <zip>6600</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jasz-Nagykun-Szolnok Megyei Hetenyi G. Korhaz-Rendelointezet</name>
      <address>
        <city>Szolnok</city>
        <zip>5000</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Villa dei Fiori</name>
      <address>
        <city>Acerra</city>
        <zip>80011</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale san Lazzaro</name>
      <address>
        <city>Alba</city>
        <zip>15100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico di Bari</name>
      <address>
        <city>Bari</city>
        <zip>70100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>P.O. di Castelfranco Veneto</name>
      <address>
        <city>Castelfranco Veneto</city>
        <zip>31033</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Civile degli Infermi</name>
      <address>
        <city>Faenza (RA)</city>
        <zip>48022</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Vito Fazzi</name>
      <address>
        <city>Lecce</city>
        <zip>73100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spedali Riuniti di Livorno</name>
      <address>
        <city>Livorno</city>
        <zip>57124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedali Riuniti di Ancona</name>
      <address>
        <city>Macerata</city>
        <zip>62100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SUN Seconda Università Napoli</name>
      <address>
        <city>Napoli</city>
        <zip>80138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Gaetano Bernabeo</name>
      <address>
        <city>Ortona (CH)</city>
        <zip>66026</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osp. Civico e Benfratelli &quot;M. Ascoli e G. Di Cristina&quot;</name>
      <address>
        <city>Palermo</city>
        <zip>90135</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Universitaria-Universita' La Sapienza</name>
      <address>
        <city>Roma</city>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. Cattolica del Sacro Cuore</name>
      <address>
        <city>Roma</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Civile</name>
      <address>
        <city>Sassari</city>
        <zip>07100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A. O. Ospedale Circolo Fond. Macchi</name>
      <address>
        <city>Varese</city>
        <zip>21100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A. O. Ospedale di Vimercate</name>
      <address>
        <city>Vimercate (Mi)</city>
        <zip>20059</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hallym University Sacred Heart Hospital</name>
      <address>
        <city>Anyang-si</city>
        <zip>14068</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inje University Busan Paik Hospital</name>
      <address>
        <city>Busan</city>
        <zip>47392</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dong-A University Hospital</name>
      <address>
        <city>Busan</city>
        <zip>49201</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Keimyung University Dongsan Medical Center</name>
      <address>
        <city>Daegu</city>
        <zip>41931</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Daegu Catholic University Medical Center</name>
      <address>
        <city>Daegu</city>
        <zip>42472</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Soonchunhyang University Hospital Seoul</name>
      <address>
        <city>Seoul</city>
        <zip>04401</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyung Hee University Hospital at Gangdong</name>
      <address>
        <city>Seoul</city>
        <zip>05278</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea, Seoul St.Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>06591</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Daugavpils Regional Hospital</name>
      <address>
        <city>Daugavpils</city>
        <zip>5420</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Liepaja Regional Hospital, Therapy Department</name>
      <address>
        <city>Liepaja</city>
        <zip>3414</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Riga East University Hospital</name>
      <address>
        <city>Riga</city>
        <zip>1038</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VSV Centrs, Stalte Private Practice, Talsi</name>
      <address>
        <city>Talsi</city>
        <zip>3201</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gita Rancane Doctor Practice in Cardiology</name>
      <address>
        <city>Ventspils</city>
        <zip>3601</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clemenceau Medical Center</name>
      <address>
        <city>Beirut</city>
        <zip>11-2555</zip>
        <country>Lebanon</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rafik Hariri University Hospital</name>
      <address>
        <city>Beirut</city>
        <zip>5244</zip>
        <country>Lebanon</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>American University of Beirut Medical Center</name>
      <address>
        <city>Beirut</city>
        <country>Lebanon</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bellevue Medical Center</name>
      <address>
        <city>Beirut</city>
        <country>Lebanon</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ain Wazein Hospital</name>
      <address>
        <city>El-Chouf</city>
        <country>Lebanon</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Notre Dame de Secours</name>
      <address>
        <city>Jbeil</city>
        <country>Lebanon</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hammoud Hospital University Medical Center</name>
      <address>
        <city>Saida</city>
        <zip>652</zip>
        <country>Lebanon</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Raja Perempuan Zainab II, Kota Bharu</name>
      <address>
        <city>Kota Bahru</city>
        <zip>15586</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Malaya Medical Centre</name>
      <address>
        <city>Kuala Lumpur</city>
        <zip>59100</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Vascular de Guadalajara</name>
      <address>
        <city>Guadalajara</city>
        <zip>44670</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Jalisciense de Metabolismo, SC</name>
      <address>
        <city>Guadalajara</city>
        <zip>44670</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital_Angeles Centro Médicodel Potosí</name>
      <address>
        <city>San Luis Potosí</city>
        <zip>78200</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arke Estudios Clinicos SA de CV</name>
      <address>
        <city>Veracruz</city>
        <zip>91910</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OLVG, locatie Oosterpark</name>
      <address>
        <city>Amsterdam</city>
        <zip>1091 AC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Amphia Ziekenhuis</name>
      <address>
        <city>Breda</city>
        <zip>4818 CK</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Antonius ziekenhuis, locatie Nieuwegein</name>
      <address>
        <city>Nieuwegein</city>
        <zip>3435 CM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tweesteden Ziekenhuis, locatie Tilburg</name>
      <address>
        <city>Tilburg</city>
        <zip>5042 AD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Palmerston North Hospital</name>
      <address>
        <city>Palmerston North</city>
        <zip>4442</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Medico Piura</name>
      <address>
        <city>Piura</city>
        <zip>51</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Makati Medical Center</name>
      <address>
        <city>Makati</city>
        <zip>1229</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Philippine General Hospital</name>
      <address>
        <city>Manila, Philippines</city>
        <zip>1000</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Luke's Medical Center, QC</name>
      <address>
        <city>Quezon City</city>
        <zip>1400</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szpital Uniwersytecki nr 2 im.dr J. Biziela</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-168</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPZOZ Wojewodzki Szpital Specjalistyczny nr 4</name>
      <address>
        <city>Bytom</city>
        <zip>41-902</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mazowiecki Szpital Specjalistyczny im. dr Jozefa Psarskiego</name>
      <address>
        <city>Ostroleka</city>
        <zip>07-410</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>4. Military Clinical Hospital with Polyclinic SP ZOZ</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-981</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Ponta Delgada</name>
      <address>
        <city>Ponta Delgada</city>
        <zip>9500-370</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar Universitário do Porto, EPE - Hospital de Santo António</name>
      <address>
        <city>Porto</city>
        <zip>4099-001</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital CUF Porto</name>
      <address>
        <city>Porto</city>
        <zip>4100-180</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar de Vila Nova de Gaia</name>
      <address>
        <city>Vila Nova de Gaia</city>
        <zip>4400-129</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Practice Cardiology Dr. Pop Calin Florin</name>
      <address>
        <city>Baia Mare</city>
        <zip>430123</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emergency University Hospital, Bucharest</name>
      <address>
        <city>Bucharest</city>
        <zip>050098</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic Municipal Cluj Napoca</name>
      <address>
        <city>Cluj-Napoca</city>
        <zip>400136</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Clinical Hospital#3</name>
      <address>
        <city>Chelyabinsk</city>
        <zip>454021</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center &quot;Angioline&quot;</name>
      <address>
        <city>Ekaterinburg</city>
        <zip>620063</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LLC Medical Union New Hospital</name>
      <address>
        <city>Ekaterinburg</city>
        <zip>620109</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Autonomous Institution of Health</name>
      <address>
        <city>Kemerovo</city>
        <zip>650066</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital #15 named after O.M.Filatov</name>
      <address>
        <city>Moscow</city>
        <zip>111539</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Federal Research and Clinical Center of Special Medical Help</name>
      <address>
        <city>Moscow</city>
        <zip>115682</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Clinical Hospital 1 (1-Gradskaya)</name>
      <address>
        <city>Moscow</city>
        <zip>117049</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Clinical Hospital n.a. V.V. Veresaev</name>
      <address>
        <city>Moscow</city>
        <zip>127644</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novosibirsk Research Institute</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630055</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rostov Medical University</name>
      <address>
        <city>Rostov on Don</city>
        <zip>344022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Clinical Hospital No. 2, St. Petersburg</name>
      <address>
        <city>St. Petersburg</city>
        <zip>194354</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Hospital Saint Elizaveta, Dept. Endocrinology</name>
      <address>
        <city>St. Petersburg</city>
        <zip>195257</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St.Petersburg State Medical University n. a. II Mechnikov</name>
      <address>
        <city>St.Petersburg</city>
        <zip>195067</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dorozghnaya hospital</name>
      <address>
        <city>St.Petersburg</city>
        <zip>195271</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical hospital of BGMU</name>
      <address>
        <city>Ufa</city>
        <zip>450081</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical emergency hospital #15</name>
      <address>
        <city>Volgograd</city>
        <zip>400026</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Voronezh Regional Hospital N1</name>
      <address>
        <city>Voronezh</city>
        <zip>394066</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yaroslavl Regional Clin. Hospital</name>
      <address>
        <city>Yaroslavl</city>
        <zip>150062</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King Fahad Medical City</name>
      <address>
        <city>Riyadh</city>
        <zip>11525</zip>
        <country>Saudi Arabia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Center of Serbia</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Medical Center Zvezdara, Belgrade</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute for Cardiovascular diseases Dedinje</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Hospital MediGroup</name>
      <address>
        <city>Belgrade</city>
        <zip>11070</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Center Bezanijska kosa, Belgrade</name>
      <address>
        <city>Belgrade</city>
        <zip>11080</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Center Kragujevac</name>
      <address>
        <city>Kragujevac</city>
        <zip>34000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Centre Nis</name>
      <address>
        <city>Nis</city>
        <zip>18000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inst. for Pulm. Diseases of Vojvodine, Clinic f. Pulm. Oncol</name>
      <address>
        <city>Sremska Kamenica</city>
        <zip>21204</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Hospital Valjevo</name>
      <address>
        <city>Valjevo</city>
        <zip>14000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ALIAN s.r.o., Bardejov, Dzupinova, Maria</name>
      <address>
        <city>Bardejov</city>
        <zip>08501</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KARDIO-ANGIO, s.r.o.</name>
      <address>
        <city>Levice</city>
        <zip>934 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HeMart, s.r.o.</name>
      <address>
        <city>Martin</city>
        <zip>036 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ABE-AS, s.r.o.</name>
      <address>
        <city>Nitra</city>
        <zip>949 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MEDIVASA s.r.o., Outpatient Clinic, Zilina</name>
      <address>
        <city>Zilina</city>
        <zip>010 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GH Celje</name>
      <address>
        <city>Celje</city>
        <zip>3000</zip>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. Clinic of Respiratory and Allergic Diseases, Golnik</name>
      <address>
        <city>Golnik</city>
        <zip>4204</zip>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCC Maribor</name>
      <address>
        <city>Maribor</city>
        <zip>2000</zip>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Topolsica</name>
      <address>
        <city>Topolsica</city>
        <zip>3326</zip>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Phramongkutklao Hospital</name>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ramathibodi Hospital</name>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thammasat University Hospital</name>
      <address>
        <city>Pathum Tani</city>
        <zip>12120</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gazi University Medical Faculty</name>
      <address>
        <city>Ankara</city>
        <zip>06560</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ankara Atatürk Training and Research Hospital</name>
      <address>
        <city>Ankara</city>
        <zip>06800</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uludag University Medical Faculty</name>
      <address>
        <city>Bursa</city>
        <zip>16059</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dicle University Medical Faculty</name>
      <address>
        <city>Diyarbakir</city>
        <zip>21830</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Ersin Arslan Public Hospital</name>
      <address>
        <city>Gaziantep</city>
        <zip>27010</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Suleyman Demirel University Medical Faculty</name>
      <address>
        <city>Isparta</city>
        <zip>32260</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bakirköy Dr. Sadi Konuk Egitim ve Arastirma Hastanesi Zuhura</name>
      <address>
        <city>Istanbul</city>
        <zip>34147</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medipol University Medical Faculty</name>
      <address>
        <city>Istanbul</city>
        <zip>34214</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Izmir Tepecik Training and Research Hospital</name>
      <address>
        <city>Izmir</city>
        <zip>35520</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ege University Medical Faculty</name>
      <address>
        <city>Izmir</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karaman Government Hospital</name>
      <address>
        <city>Karaman</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kayseri Training And Research Hospital</name>
      <address>
        <city>Kayseri</city>
        <zip>38010</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RTE University Medical Faculty</name>
      <address>
        <city>Rize</city>
        <zip>53200</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ozel Uzmanlar Yalova Hospital</name>
      <address>
        <city>Yalova</city>
        <zip>77200</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thumbay Hospital</name>
      <address>
        <city>Dubai</city>
        <zip>41840</zip>
        <country>United Arab Emirates</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barnsley Hospital</name>
      <address>
        <city>Barnsley</city>
        <zip>S75 2EP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Hampshire Hospital</name>
      <address>
        <city>Basingstoke</city>
        <zip>RG24 9NA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Birmingham Heartlands Hospital</name>
      <address>
        <city>Birmingham</city>
        <zip>B9 5SS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen's Hospital</name>
      <address>
        <city>Burton on Trent</city>
        <zip>DE13 0RB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of North Durham</name>
      <address>
        <city>Durham</city>
        <zip>DH1 5TW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Thomas' Hospital</name>
      <address>
        <city>London</city>
        <zip>SE1 7EH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wythenshawe Hospital</name>
      <address>
        <city>Manchester</city>
        <zip>M23 9LT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Tyneside General Hospital</name>
      <address>
        <city>North Shields</city>
        <zip>NE29 8NH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Craigavon Area Hospital</name>
      <address>
        <city>Portadown</city>
        <zip>BT63 5QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Salisbury District Hospital</name>
      <address>
        <city>Salisbury</city>
        <zip>SP2 8BJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bach Mai hospital</name>
      <address>
        <city>Hanoi</city>
        <zip>100000</zip>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center of Ho Chi Minh City</name>
      <address>
        <city>Ho Chi Minh city</city>
        <zip>70000</zip>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>115 People Hospital</name>
      <address>
        <city>Ho Chi Minh</city>
        <zip>700000</zip>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gia Dinh People Hospital</name>
      <address>
        <city>Ho Chi Minh</city>
        <zip>700000</zip>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cho Ray Hospital</name>
      <address>
        <city>Ho Chi Minh</city>
        <zip>70000</zip>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>Colombia</country>
    <country>Czechia</country>
    <country>Egypt</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Latvia</country>
    <country>Lebanon</country>
    <country>Malaysia</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>New Zealand</country>
    <country>Peru</country>
    <country>Philippines</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Saudi Arabia</country>
    <country>Serbia</country>
    <country>Slovakia</country>
    <country>Slovenia</country>
    <country>Thailand</country>
    <country>Turkey</country>
    <country>United Arab Emirates</country>
    <country>United Kingdom</country>
    <country>United States</country>
    <country>Vietnam</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
    <country>India</country>
    <country>Singapore</country>
  </removed_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>October 28, 2015</study_first_submitted>
  <study_first_submitted_qc>November 3, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 4, 2015</study_first_posted>
  <results_first_submitted>March 25, 2020</results_first_submitted>
  <results_first_submitted_qc>April 16, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">April 29, 2020</results_first_posted>
  <last_update_submitted>April 16, 2020</last_update_submitted>
  <last_update_submitted_qc>April 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 5, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/30/NCT02596230/SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 16, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/30/NCT02596230/Prot_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study characterizes patients following acute venous thromboembolism and assesses the safety and effectiveness of dabigatran etexilate in the treatment and secondary prevention of acute DVT and PE in comparison to vitamin K antagonist in routine clinical practice. This is a large multi-center observational study based on new data collection.</recruitment_details>
      <pre_assignment_details>All subjects were screened for eligibility to participate in the trial. Subjects attended specialist sites which would then ensure that they met all inclusion/exclusion criteria. The study enrolled and characterized all patients within 30 days after being diagnosed with an acute DVT and/or PE.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Not Assigned to Dabigatran Etexilate or Vitamin K Antagonist</title>
          <description>Participants diagnosed with an acute Deep Vein Thrombosis (DVT) irrespective of location and/or Pulmonary Embolism (PE) and treated with either Edoxaban, Rivaroxaban, Apixaban or other anticoagulation treatments. Participants analyzed for objective 1 only.</description>
        </group>
        <group group_id="P2">
          <title>Dabigatran Etexilate (1)</title>
          <description>Participants diagnosed with an acute Deep Vein Thrombosis (DVT) irrespective of location and/or Pulmonary Embolism (PE) and treated with Dabigatran etexilate. Participants analyzed for objective 1 or for objective 1 and 2.</description>
        </group>
        <group group_id="P3">
          <title>Dabigatran Etexilate (2)</title>
          <description>Participants diagnosed with an acute Deep Vein Thrombosis (DVT) irrespective of location and/or Pulmonary Embolism (PE) and treated with Dabigatran etexilate. New participants analyzed for objective 2 only.</description>
        </group>
        <group group_id="P4">
          <title>Vitamin K Antagonist (1)</title>
          <description>Participants diagnosed with an acute Deep Vein Thrombosis (DVT) irrespective of location and/or Pulmonary Embolism (PE) and treated with Vitamin K antagonist. Participants analyzed for objective 1 or for objective 1 and 2.</description>
        </group>
        <group group_id="P5">
          <title>Vitamin K Antagonist (2)</title>
          <description>Participants diagnosed with an acute Deep Vein Thrombosis (DVT) irrespective of location and/or Pulmonary Embolism (PE) and treated with Vitamin K antagonist. New participants analyzed for objective 2 only.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Objective 1, One Visit During 14 Days</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3714"/>
                <participants group_id="P2" count="1006"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1375"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3714"/>
                <participants group_id="P2" count="1006"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1375"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Screening Period for Objective 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3714"/>
                <participants group_id="P2" count="1006"/>
                <participants group_id="P3" count="910">Participants entering the study after the completion of objective 1.</participants>
                <participants group_id="P4" count="1375"/>
                <participants group_id="P5" count="792">Participants entering the study after the completion of objective 1.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="778"/>
                <participants group_id="P3" count="910"/>
                <participants group_id="P4" count="529"/>
                <participants group_id="P5" count="792"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3714"/>
                <participants group_id="P2" count="228"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="846"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Participants not participating in obj 2</title>
              <participants_list>
                <participants group_id="P1" count="3714"/>
                <participants group_id="P2" count="228"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="846"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Objective 2, One Year</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="778"/>
                <participants group_id="P3" count="910"/>
                <participants group_id="P4" count="529"/>
                <participants group_id="P5" count="792"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="710"/>
                <participants group_id="P3" count="812"/>
                <participants group_id="P4" count="471"/>
                <participants group_id="P5" count="714"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="68"/>
                <participants group_id="P3" count="98"/>
                <participants group_id="P4" count="58"/>
                <participants group_id="P5" count="78"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="41"/>
                <participants group_id="P3" count="41"/>
                <participants group_id="P4" count="32"/>
                <participants group_id="P5" count="46"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="14"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse drug reaction</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="41"/>
                <participants group_id="P4" count="21"/>
                <participants group_id="P5" count="30"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All Eligible: patients fulfilling all inclusion criteria and no exclusion criteria.</population>
      <group_list>
        <group group_id="B1">
          <title>Not Assigned to Dabigatran Etexilate or Vitamin K Antagonist</title>
          <description>Participants diagnosed with an acute Deep Vein Thrombosis (DVT) irrespective of location and/or Pulmonary Embolism (PE) and treated with either Edoxaban, Rivaroxaban, Apixaban or other anticoagulation treatments. Participants analyzed for objective 1 only.</description>
        </group>
        <group group_id="B2">
          <title>Dabigatran Etexilate (1)</title>
          <description>Participants diagnosed with an acute Deep Vein Thrombosis (DVT) irrespective of location and/or Pulmonary Embolism (PE) and treated with Dabigatran etexilate. Participants analyzed for objective 1 or for objective 1 and 2.</description>
        </group>
        <group group_id="B3">
          <title>Dabigatran Etexilate (2)</title>
          <description>Participants diagnosed with an acute Deep Vein Thrombosis (DVT) irrespective of location and/or Pulmonary Embolism (PE) and treated with Dabigatran etexilate. New participants analyzed for objective 2 only.</description>
        </group>
        <group group_id="B4">
          <title>Vitamin K Antagonist (1)</title>
          <description>Participants diagnosed with an acute Deep Vein Thrombosis (DVT) irrespective of location and/or Pulmonary Embolism (PE) and treated with Vitamin K antagonist. Participants analyzed for objective 1 or for objective 1 and 2.</description>
        </group>
        <group group_id="B5">
          <title>Vitamin K Antagonist (2)</title>
          <description>Participants diagnosed with an acute Deep Vein Thrombosis (DVT) irrespective of location and/or Pulmonary Embolism (PE) and treated with Vitamin K antagonist. New participants analyzed for objective 2 only.</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3714"/>
            <count group_id="B2" value="1006"/>
            <count group_id="B3" value="910"/>
            <count group_id="B4" value="1375"/>
            <count group_id="B5" value="792"/>
            <count group_id="B6" value="7797"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.5" spread="17.2"/>
                    <measurement group_id="B2" value="58.3" spread="16.6"/>
                    <measurement group_id="B3" value="58.4" spread="16.6"/>
                    <measurement group_id="B4" value="61.3" spread="16.6"/>
                    <measurement group_id="B5" value="59.0" spread="16.6"/>
                    <measurement group_id="B6" value="60.9" spread="17.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex/Gender, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1806"/>
                    <measurement group_id="B2" value="548"/>
                    <measurement group_id="B3" value="477"/>
                    <measurement group_id="B4" value="708"/>
                    <measurement group_id="B5" value="417"/>
                    <measurement group_id="B6" value="3956"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1907"/>
                    <measurement group_id="B2" value="458"/>
                    <measurement group_id="B3" value="433"/>
                    <measurement group_id="B4" value="667"/>
                    <measurement group_id="B5" value="375"/>
                    <measurement group_id="B6" value="3840"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="7"/>
                    <measurement group_id="B6" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="420"/>
                    <measurement group_id="B2" value="149"/>
                    <measurement group_id="B3" value="147"/>
                    <measurement group_id="B4" value="96"/>
                    <measurement group_id="B5" value="124"/>
                    <measurement group_id="B6" value="936"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="111"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="71"/>
                    <measurement group_id="B5" value="18"/>
                    <measurement group_id="B6" value="209"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2620"/>
                    <measurement group_id="B2" value="828"/>
                    <measurement group_id="B3" value="742"/>
                    <measurement group_id="B4" value="1152"/>
                    <measurement group_id="B5" value="600"/>
                    <measurement group_id="B6" value="5942"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="42"/>
                    <measurement group_id="B6" value="71"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="552"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="47"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="621"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Objective 1: Age</title>
        <description>Age in years of eligible patients collected for Objective 1 during baseline at the time of index event. Aim of Objective 1 was to characterize the Venous Thromboembolism (VTE) patient population including the initial acute event phase, i.e. all patients regardless of treatment. Patients who enrolled in Objective 1 and were treated with VKA or dabigatran were also eligible for Objective 2. The aim of objective 2 was to analyze the safety and effectiveness of dabigatran regimens in the treatment of DVT and PE over 1 year of follow-up in comparison to a VKA regimen.
The arm presented in this endpoint was separated into three arms in the participant flow tables (&quot;Not assigned to Dabigatran etexilate or Vitamin K antagonist&quot;,&quot;Dabigatran etexilate (1)&quot; and &quot;Vitamin K antagonist (1)&quot;) in order to distinguish patients participating in both objectives from patients only in objective 2.</description>
        <time_frame>Baseline collected within 14 days but not more than 6 months after diagnosis of acute deep vein thrombosis (DVT) and/or pulmonary embolism (PE).</time_frame>
        <population>All eligible patients with a DVT and/or PE (regardless of treatment) were enrolled for cross-sectional characterisation of the VTE patient population</population>
        <group_list>
          <group group_id="O1">
            <title>All Participants With a DVT and/or PE</title>
            <description>All participants diagnosed with Deep Vein Thrombosis (DVT) irrespective of location and/or Pulmonary Embolism (PE).</description>
          </group>
        </group_list>
        <measure>
          <title>Objective 1: Age</title>
          <description>Age in years of eligible patients collected for Objective 1 during baseline at the time of index event. Aim of Objective 1 was to characterize the Venous Thromboembolism (VTE) patient population including the initial acute event phase, i.e. all patients regardless of treatment. Patients who enrolled in Objective 1 and were treated with VKA or dabigatran were also eligible for Objective 2. The aim of objective 2 was to analyze the safety and effectiveness of dabigatran regimens in the treatment of DVT and PE over 1 year of follow-up in comparison to a VKA regimen.
The arm presented in this endpoint was separated into three arms in the participant flow tables (&quot;Not assigned to Dabigatran etexilate or Vitamin K antagonist&quot;,&quot;Dabigatran etexilate (1)&quot; and &quot;Vitamin K antagonist (1)&quot;) in order to distinguish patients participating in both objectives from patients only in objective 2.</description>
          <population>All eligible patients with a DVT and/or PE (regardless of treatment) were enrolled for cross-sectional characterisation of the VTE patient population</population>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6095"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.5" spread="17.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Objective 1: Sex</title>
        <description>Sex of eligible patients collected for Objective 1 during baseline at the time of index event. Aim of Objective 1 was to characterize the Venous Thromboembolism (VTE) patient population including the initial acute event phase, i.e. all patients regardless of treatment. Patients who enrolled in Objective 1 and were treated with VKA or dabigatran were also eligible for Objective 2. The aim of objective 2 was to analyze the safety and effectiveness of dabigatran regimens in the treatment of DVT and PE over 1 year of follow-up in comparison to a VKA regimen.
The arm presented in this endpoint was separated into three arms in the participant flow tables (&quot;Not assigned to Dabigatran etexilate or Vitamin K antagonist&quot;,&quot;Dabigatran etexilate (1)&quot; and &quot;Vitamin K antagonist (1)&quot;) in order to distinguish patients participating in both objectives from patients only in objective 2.</description>
        <time_frame>Baseline collected within 14 days but not more than 6 months after diagnosis of acute deep vein thrombosis (DVT) and/or pulmonary embolism (PE).</time_frame>
        <population>All eligible patients with a DVT and/or PE (regardless of treatment) were enrolled for cross-sectional characterisation of the VTE patient population.</population>
        <group_list>
          <group group_id="O1">
            <title>All Participants With a DVT and/or PE</title>
            <description>All participants diagnosed with Deep Vein Thrombosis (DVT) irrespective of location and/or Pulmonary Embolism (PE).</description>
          </group>
        </group_list>
        <measure>
          <title>Objective 1: Sex</title>
          <description>Sex of eligible patients collected for Objective 1 during baseline at the time of index event. Aim of Objective 1 was to characterize the Venous Thromboembolism (VTE) patient population including the initial acute event phase, i.e. all patients regardless of treatment. Patients who enrolled in Objective 1 and were treated with VKA or dabigatran were also eligible for Objective 2. The aim of objective 2 was to analyze the safety and effectiveness of dabigatran regimens in the treatment of DVT and PE over 1 year of follow-up in comparison to a VKA regimen.
The arm presented in this endpoint was separated into three arms in the participant flow tables (&quot;Not assigned to Dabigatran etexilate or Vitamin K antagonist&quot;,&quot;Dabigatran etexilate (1)&quot; and &quot;Vitamin K antagonist (1)&quot;) in order to distinguish patients participating in both objectives from patients only in objective 2.</description>
          <population>All eligible patients with a DVT and/or PE (regardless of treatment) were enrolled for cross-sectional characterisation of the VTE patient population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6095"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <title>Participants</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3062"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <title>Participants</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3032"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing data</title>
              <category_list>
                <category>
                  <title>Participants</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Objective 1: Index Event</title>
        <description>Type of index event (e.g., DVT or PE or DVT and PE) diagnosed at the time of acute Venous Thromboembolism (VTE) event of eligible patients collected for Objective 1 during baseline at the time of index event. Aim of Objective 1 was to characterize the Venous Thromboembolism (VTE) patient population including the initial acute event phase, i.e. all patients regardless of treatment. Patients who enrolled in Objective 1 and were treated with VKA or dabigatran were also eligible for Objective 2. The aim of objective 2 was to analyze the safety and effectiveness of dabigatran regimens in the treatment of DVT and PE over 1 year of follow-up in comparison to a VKA regimen.
The arm presented in this endpoint was separated into three arms in the participant flow tables (&quot;Not assigned to Dabigatran etexilate or Vitamin K antagonist&quot;,&quot;Dabigatran etexilate (1)&quot; and &quot;Vitamin K antagonist (1)&quot;) in order to distinguish patients participating in both objectives from patients only in objective 2.</description>
        <time_frame>Baseline collected within 14 days but not more than 6 months after diagnosis of acute deep vein thrombosis (DVT) and/or pulmonary embolism (PE).</time_frame>
        <population>All eligible patients with a DVT and/or PE (regardless of treatment) were enrolled for cross-sectional characterisation of the VTE patient population.</population>
        <group_list>
          <group group_id="O1">
            <title>All Participants With a DVT and/or PE</title>
            <description>All participants diagnosed with Deep Vein Thrombosis (DVT) irrespective of location and/or Pulmonary Embolism (PE).</description>
          </group>
        </group_list>
        <measure>
          <title>Objective 1: Index Event</title>
          <description>Type of index event (e.g., DVT or PE or DVT and PE) diagnosed at the time of acute Venous Thromboembolism (VTE) event of eligible patients collected for Objective 1 during baseline at the time of index event. Aim of Objective 1 was to characterize the Venous Thromboembolism (VTE) patient population including the initial acute event phase, i.e. all patients regardless of treatment. Patients who enrolled in Objective 1 and were treated with VKA or dabigatran were also eligible for Objective 2. The aim of objective 2 was to analyze the safety and effectiveness of dabigatran regimens in the treatment of DVT and PE over 1 year of follow-up in comparison to a VKA regimen.
The arm presented in this endpoint was separated into three arms in the participant flow tables (&quot;Not assigned to Dabigatran etexilate or Vitamin K antagonist&quot;,&quot;Dabigatran etexilate (1)&quot; and &quot;Vitamin K antagonist (1)&quot;) in order to distinguish patients participating in both objectives from patients only in objective 2.</description>
          <population>All eligible patients with a DVT and/or PE (regardless of treatment) were enrolled for cross-sectional characterisation of the VTE patient population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6095"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>DVT</title>
              <category_list>
                <category>
                  <title>Participants</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3644"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PE</title>
              <category_list>
                <category>
                  <title>Participants</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1588"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DVT and PE</title>
              <category_list>
                <category>
                  <title>Participants</title>
                  <measurement_list>
                    <measurement group_id="O1" value="863"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Objective 1: Anticoagulant Treatment</title>
        <description>Type of treatment received following acute Venous Thromboembolism (VTE) event of eligible patients collected for Objective 1 during baseline at the time of index event. Aim of Objective 1 was to characterize the Venous Thromboembolism (VTE) patient population including the initial acute event phase, i.e. all patients regardless of treatment. Patients who enrolled in Objective 1 and were treated with VKA or dabigatran were also eligible for Objective 2. The aim of objective 2 was to analyze the safety and effectiveness of dabigatran regimens in the treatment of DVT and PE over 1 year of follow-up in comparison to a VKA regimen.
The arm presented in this endpoint was separated into three arms in the participant flow tables (&quot;Not assigned to Dabigatran etexilate or Vitamin K antagonist&quot;,&quot;Dabigatran etexilate (1)&quot; and &quot;Vitamin K antagonist (1)&quot;) in order to distinguish patients participating in both objectives from patients only in objective 2.</description>
        <time_frame>Baseline collected within 14 days but not more than 6 months after diagnosis of acute deep vein thrombosis (DVT) and/or pulmonary embolism (PE).</time_frame>
        <population>All eligible patients with a DVT and/or PE (regardless of treatment) were enrolled for cross-sectional characterisation of the VTE patient population.</population>
        <group_list>
          <group group_id="O1">
            <title>All Participants With a DVT and/or PE</title>
            <description>All participants diagnosed with Deep Vein Thrombosis (DVT) irrespective of location and/or Pulmonary Embolism (PE).</description>
          </group>
        </group_list>
        <measure>
          <title>Objective 1: Anticoagulant Treatment</title>
          <description>Type of treatment received following acute Venous Thromboembolism (VTE) event of eligible patients collected for Objective 1 during baseline at the time of index event. Aim of Objective 1 was to characterize the Venous Thromboembolism (VTE) patient population including the initial acute event phase, i.e. all patients regardless of treatment. Patients who enrolled in Objective 1 and were treated with VKA or dabigatran were also eligible for Objective 2. The aim of objective 2 was to analyze the safety and effectiveness of dabigatran regimens in the treatment of DVT and PE over 1 year of follow-up in comparison to a VKA regimen.
The arm presented in this endpoint was separated into three arms in the participant flow tables (&quot;Not assigned to Dabigatran etexilate or Vitamin K antagonist&quot;,&quot;Dabigatran etexilate (1)&quot; and &quot;Vitamin K antagonist (1)&quot;) in order to distinguish patients participating in both objectives from patients only in objective 2.</description>
          <population>All eligible patients with a DVT and/or PE (regardless of treatment) were enrolled for cross-sectional characterisation of the VTE patient population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6095"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Dabigatran</title>
              <category_list>
                <category>
                  <title>Participants</title>
                  <measurement_list>
                    <measurement group_id="O1" value="947"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>vitamin K antagonist (VKA)</title>
              <category_list>
                <category>
                  <title>Participants</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1388"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Edoxaban</title>
              <category_list>
                <category>
                  <title>Participants</title>
                  <measurement_list>
                    <measurement group_id="O1" value="103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rivaroxaban</title>
              <category_list>
                <category>
                  <title>Participants</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1558"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Apixaban</title>
              <category_list>
                <category>
                  <title>Participants</title>
                  <measurement_list>
                    <measurement group_id="O1" value="686"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <title>Participants</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1413"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Objective 2: Incidence Rate of ISTH (International Society on Thrombosis and Haemostasis) Major Bleeding and CRNMB (Clinically Relevant Non Major Bleeding) Per 100 Patient-years (Pt-yrs)</title>
        <description>Incidence rate of ISTH (International Society on Thrombosis and Haemostasis) major bleeding and CRNMB (clinically relevant non major bleeding) per 100 patient-years (1/(100*patient-years)). Each patient in the two treatment groups was weighted proportionally to the probability of that patient being assigned to the opposite treatment group, conditional on relevant observed baseline variables. The propensity scores were estimated using the multivariable logistic regression model.
For the restricted patient set, as a sensitivity analysis, the calculation of incidence rates and cumulative risks was performed without censoring at permanent discontinuation.</description>
        <time_frame>12 months following acute deep vein thrombosis (DVT) and/or pulmonary embolism (PE).</time_frame>
        <population>Restricted set: The restricted population was composed of all eligible patients, which lay within the region of propensity score overlap and who took the prescribed treatment at least once.</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran Etexilate</title>
            <description>Participants diagnosed with an acute Deep Vein Thrombosis (DVT) irrespective of location and/or Pulmonary Embolism (PE) and treated with Dabigatran etexilate. This includes both participants who participated in objective 1 and 2 and new participants only participating in objective 2.</description>
          </group>
          <group group_id="O2">
            <title>Vitamin K Antagonist</title>
            <description>Participants diagnosed with an acute DVT and/or PE and treated with Vitamin K antagonist. This includes both participants who participated in objective 1 and 2 and new participants only participating in objective 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Objective 2: Incidence Rate of ISTH (International Society on Thrombosis and Haemostasis) Major Bleeding and CRNMB (Clinically Relevant Non Major Bleeding) Per 100 Patient-years (Pt-yrs)</title>
          <description>Incidence rate of ISTH (International Society on Thrombosis and Haemostasis) major bleeding and CRNMB (clinically relevant non major bleeding) per 100 patient-years (1/(100*patient-years)). Each patient in the two treatment groups was weighted proportionally to the probability of that patient being assigned to the opposite treatment group, conditional on relevant observed baseline variables. The propensity scores were estimated using the multivariable logistic regression model.
For the restricted patient set, as a sensitivity analysis, the calculation of incidence rates and cumulative risks was performed without censoring at permanent discontinuation.</description>
          <population>Restricted set: The restricted population was composed of all eligible patients, which lay within the region of propensity score overlap and who took the prescribed treatment at least once.</population>
          <units>events per 100 patient-years</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1681"/>
                <count group_id="O2" value="1288"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.63" lower_limit="1.79" upper_limit="3.73"/>
                    <measurement group_id="O2" value="4.42" lower_limit="3.18" upper_limit="5.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.188</p_value>
            <p_value_desc>One-side p-value</p_value_desc>
            <method>Regression, Cox</method>
            <method_desc>Cox-regression proportional hazards model including fixed effects for treatment.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.634</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.322</ci_lower_limit>
            <ci_upper_limit>1.249</ci_upper_limit>
            <estimate_desc>Hazard Ratio &lt; 1 favors Dabigatran etexilate.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Objective 2: Symptomatic Recurrent VTE (Venous Thromboembolism) Including VTE Related Mortality</title>
        <description>Incidence rate of Symptomatic Recurrent VTE (Venous Thromboembolism) including VTE related mortality per 100 patient-years (1/(100*patient-years)). Each patient in the two treatment groups was weighted proportionally to the probability of that patient being assigned to the opposite treatment group, conditional on relevant observed baseline variables. The propensity scores were estimated using the multivariable logistic regression model.
For the restricted patient set, as a sensitivity analysis, the calculation of incidence rates and cumulative risks was performed without censoring at permanent discontinuation.</description>
        <time_frame>12 months following acute deep vein thrombosis (DVT) and/or pulmonary embolism (PE).</time_frame>
        <population>Restricted set: The restricted population was composed of all eligible patients, which lay within the region of propensity score overlap. The propensity scores are estimated after the multiple imputation is performed based on eligible patients who took the prescribed treatment at least once.</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran Etexilate</title>
            <description>Participants diagnosed with an acute Deep Vein Thrombosis (DVT) irrespective of location and/or Pulmonary Embolism (PE) and treated with Dabigatran etexilate. This includes both participants who participated in objective 1 and 2 and new participants only participating in objective 2.</description>
          </group>
          <group group_id="O2">
            <title>Vitamin K Antagonist</title>
            <description>Participants diagnosed with an acute DVT and/or PE and treated with Vitamin K antagonist. This includes both participants who participated in objective 1 and 2 and new participants only participating in objective 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Objective 2: Symptomatic Recurrent VTE (Venous Thromboembolism) Including VTE Related Mortality</title>
          <description>Incidence rate of Symptomatic Recurrent VTE (Venous Thromboembolism) including VTE related mortality per 100 patient-years (1/(100*patient-years)). Each patient in the two treatment groups was weighted proportionally to the probability of that patient being assigned to the opposite treatment group, conditional on relevant observed baseline variables. The propensity scores were estimated using the multivariable logistic regression model.
For the restricted patient set, as a sensitivity analysis, the calculation of incidence rates and cumulative risks was performed without censoring at permanent discontinuation.</description>
          <population>Restricted set: The restricted population was composed of all eligible patients, which lay within the region of propensity score overlap. The propensity scores are estimated after the multiple imputation is performed based on eligible patients who took the prescribed treatment at least once.</population>
          <units>events per 100 patient-years</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1681"/>
                <count group_id="O2" value="1288"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.53" lower_limit="0.91" upper_limit="2.42"/>
                    <measurement group_id="O2" value="2.01" lower_limit="1.21" upper_limit="3.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.606</p_value>
            <p_value_desc>One-side p-value</p_value_desc>
            <method>Regression, Cox</method>
            <method_desc>Cox-regression proportional hazards model including fixed effects for treatment.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.778</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.300</ci_lower_limit>
            <ci_upper_limit>2.017</ci_upper_limit>
            <estimate_desc>Hazard Ratio &lt; 1 favors Dabigatran etexilate.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Objective 2: Incidence Rate of Recurrent DVT and/or PE</title>
        <description>Incidence rate of Recurrent Deep Vein Thrombosis (DVT) and/or Pulmonary Embolism (PE) per 100 patient-years (1/(100*patient-years)). Each patient in the two treatment groups was weighted proportionally to the probability of that patient being assigned to the opposite treatment group, conditional on relevant observed baseline variables. The propensity scores were estimated using the multivariable logistic regression model.
For the restricted patient set, as a sensitivity analysis, the calculation of incidence rates and cumulative risks was performed without censoring at permanent discontinuation.</description>
        <time_frame>12 months following acute deep vein thrombosis (DVT) and/or pulmonary embolism (PE).</time_frame>
        <population>Restricted set: The restricted population was composed of all eligible patients, which lay within the region of propensity score overlap. The propensity scores are estimated after the multiple imputation is performed based on eligible patients who took the prescribed treatment at least once.</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran Etexilate</title>
            <description>Participants diagnosed with an acute Deep Vein Thrombosis (DVT) irrespective of location and/or Pulmonary Embolism (PE) and treated with Dabigatran etexilate. This includes both participants who participated in objective 1 and 2 and new participants only participating in objective 2.</description>
          </group>
          <group group_id="O2">
            <title>Vitamin K Antagonist</title>
            <description>Participants diagnosed with an acute DVT and/or PE and treated with Vitamin K antagonist. This includes both participants who participated in objective 1 and 2 and new participants only participating in objective 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Objective 2: Incidence Rate of Recurrent DVT and/or PE</title>
          <description>Incidence rate of Recurrent Deep Vein Thrombosis (DVT) and/or Pulmonary Embolism (PE) per 100 patient-years (1/(100*patient-years)). Each patient in the two treatment groups was weighted proportionally to the probability of that patient being assigned to the opposite treatment group, conditional on relevant observed baseline variables. The propensity scores were estimated using the multivariable logistic regression model.
For the restricted patient set, as a sensitivity analysis, the calculation of incidence rates and cumulative risks was performed without censoring at permanent discontinuation.</description>
          <population>Restricted set: The restricted population was composed of all eligible patients, which lay within the region of propensity score overlap. The propensity scores are estimated after the multiple imputation is performed based on eligible patients who took the prescribed treatment at least once.</population>
          <units>events per 100 patient-years</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1681"/>
                <count group_id="O2" value="1288"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.61" lower_limit="0.97" upper_limit="2.52"/>
                    <measurement group_id="O2" value="2.22" lower_limit="1.38" upper_limit="3.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.542</p_value>
            <p_value_desc>One-side p-value</p_value_desc>
            <method>Regression, Cox</method>
            <method_desc>Cox-regression proportional hazards model including fixed effects for treatment.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.751</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.299</ci_lower_limit>
            <ci_upper_limit>1.885</ci_upper_limit>
            <estimate_desc>Hazard Ratio &lt; 1 favors Dabigatran etexilate.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Objective 2: Incidence Rate of VTE-related Mortality</title>
        <description>Incidence rate of VTE-related Mortality per 100 patient-years (1/(100*patient-years)). Each patient in the two treatment groups was weighted proportionally to the probability of that patient being assigned to the opposite treatment group, conditional on relevant observed baseline variables. The propensity scores were estimated using the multivariable logistic regression model.
For the restricted patient set, as a sensitivity analysis, the calculation of incidence rates and cumulative risks was performed without censoring at permanent discontinuation.</description>
        <time_frame>12 months following acute deep vein thrombosis (DVT) and/or pulmonary embolism (PE).</time_frame>
        <population>Restricted set: The restricted population was composed of all eligible patients, which lay within the region of propensity score overlap. The propensity scores are estimated after the multiple imputation is performed based on eligible patients who took the prescribed treatment at least once.</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran Etexilate</title>
            <description>Participants diagnosed with an acute Deep Vein Thrombosis (DVT) irrespective of location and/or Pulmonary Embolism (PE) and treated with Dabigatran etexilate. This includes both participants who participated in objective 1 and 2 and new participants only participating in objective 2.</description>
          </group>
          <group group_id="O2">
            <title>Vitamin K Antagonist</title>
            <description>Participants diagnosed with an acute DVT and/or PE and treated with Vitamin K antagonist. This includes both participants who participated in objective 1 and 2 and new participants only participating in objective 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Objective 2: Incidence Rate of VTE-related Mortality</title>
          <description>Incidence rate of VTE-related Mortality per 100 patient-years (1/(100*patient-years)). Each patient in the two treatment groups was weighted proportionally to the probability of that patient being assigned to the opposite treatment group, conditional on relevant observed baseline variables. The propensity scores were estimated using the multivariable logistic regression model.
For the restricted patient set, as a sensitivity analysis, the calculation of incidence rates and cumulative risks was performed without censoring at permanent discontinuation.</description>
          <population>Restricted set: The restricted population was composed of all eligible patients, which lay within the region of propensity score overlap. The propensity scores are estimated after the multiple imputation is performed based on eligible patients who took the prescribed treatment at least once.</population>
          <units>events per 100 patient-years</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1681"/>
                <count group_id="O2" value="1288"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="0.42" lower_limit="0.11" upper_limit="1.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.996</p_value>
            <p_value_desc>One-side p-value</p_value_desc>
            <method>Regression, Cox</method>
            <method_desc>Cox-regression proportional hazards model including fixed effects for treatment.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>Hazard Ratio &lt; 1 favors Dabigatran etexilate.
Hazard Ratio is actually &lt;0.01
95% Confidence Interval is not calculable (NA) due to insufficient number of participants with events.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Objective 2: Incidence Rate of All-cause Mortality</title>
        <description>Incidence rate of all-cause mortality per 100 patient-years (1/(100*patient-years)). Each patient in the two treatment groups was weighted proportionally to the probability of that patient being assigned to the opposite treatment group, conditional on relevant observed baseline variables. The propensity scores were estimated using the multivariable logistic regression model.
For the restricted patient set, as a sensitivity analysis, the calculation of incidence rates and cumulative risks was performed without censoring at permanent discontinuation.</description>
        <time_frame>12 months following acute deep vein thrombosis (DVT) and/or pulmonary embolism (PE).</time_frame>
        <population>Restricted set: The restricted population was composed of all eligible patients, which lay within the region of propensity score overlap. The propensity scores are estimated after the multiple imputation is performed based on eligible patients who took the prescribed treatment at least once.</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran Etexilate</title>
            <description>Participants diagnosed with an acute Deep Vein Thrombosis (DVT) irrespective of location and/or Pulmonary Embolism (PE) and treated with Dabigatran etexilate. This includes both participants who participated in objective 1 and 2 and new participants only participating in objective 2.</description>
          </group>
          <group group_id="O2">
            <title>Vitamin K Antagonist</title>
            <description>Participants diagnosed with an acute DVT and/or PE and treated with Vitamin K antagonist. This includes both participants who participated in objective 1 and 2 and new participants only participating in objective 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Objective 2: Incidence Rate of All-cause Mortality</title>
          <description>Incidence rate of all-cause mortality per 100 patient-years (1/(100*patient-years)). Each patient in the two treatment groups was weighted proportionally to the probability of that patient being assigned to the opposite treatment group, conditional on relevant observed baseline variables. The propensity scores were estimated using the multivariable logistic regression model.
For the restricted patient set, as a sensitivity analysis, the calculation of incidence rates and cumulative risks was performed without censoring at permanent discontinuation.</description>
          <population>Restricted set: The restricted population was composed of all eligible patients, which lay within the region of propensity score overlap. The propensity scores are estimated after the multiple imputation is performed based on eligible patients who took the prescribed treatment at least once.</population>
          <units>events per 100 patient-years</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1681"/>
                <count group_id="O2" value="1288"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.12" lower_limit="1.37" upper_limit="3.12"/>
                    <measurement group_id="O2" value="3.06" lower_limit="2.05" upper_limit="4.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.690</p_value>
            <p_value_desc>One-side p-value</p_value_desc>
            <method>Regression, Cox</method>
            <method_desc>Cox-regression proportional hazards model including fixed effects for treatment.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.857</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.402</ci_lower_limit>
            <ci_upper_limit>1.828</ci_upper_limit>
            <estimate_desc>Hazard Ratio &lt; 1 favors Dabigatran etexilate.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From the time of VTE until the end of the study (Dabigatran etexilate (1) and (2) and Vitamin K antagonist (1) and (2)) or from the time of informed consent until the end of the study (not assigned to Dabigatran etexilate or Vitamin K antagonist), up to 12 months.</time_frame>
      <desc>Adverse events are reported based on all eligible patients.</desc>
      <group_list>
        <group group_id="E1">
          <title>Not Assigned to Dabigatran Etexilate or Vitamin K Antagonist</title>
          <description>Participants diagnosed with an acute Deep Vein Thrombosis (DVT) irrespective of location and/or Pulmonary Embolism (PE) and treated with either Edoxaban, Rivaroxaban, Apixaban or other anticoagulation treatments. Participants analyzed for objective 1 only.</description>
        </group>
        <group group_id="E2">
          <title>Dabigatran Etexilate (1)</title>
          <description>Participants diagnosed with an acute Deep Vein Thrombosis (DVT) irrespective of location and/or Pulmonary Embolism (PE) and treated with Dabigatran etexilate. Participants analyzed for objective 1 or for objective 1 and 2.</description>
        </group>
        <group group_id="E3">
          <title>Dabigatran Etexilate (2)</title>
          <description>Participants diagnosed with an acute Deep Vein Thrombosis (DVT) irrespective of location and/or Pulmonary Embolism (PE) and treated with Dabigatran etexilate. New participants analyzed for objective 2 only.</description>
        </group>
        <group group_id="E4">
          <title>Vitamin K Antagonist (1)</title>
          <description>Participants diagnosed with an acute Deep Vein Thrombosis (DVT) irrespective of location and/or Pulmonary Embolism (PE) and treated with Vitamin K antagonist. Participants analyzed for objective 1 or for objective 1 and 2.</description>
        </group>
        <group group_id="E5">
          <title>Vitamin K Antagonist (2)</title>
          <description>Participants diagnosed with an acute Deep Vein Thrombosis (DVT) irrespective of location and/or Pulmonary Embolism (PE) and treated with Vitamin K antagonist. New participants analyzed for objective 2 only.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 21.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="3714"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="1006"/>
                <counts group_id="E3" subjects_affected="42" subjects_at_risk="910"/>
                <counts group_id="E4" subjects_affected="25" subjects_at_risk="1375"/>
                <counts group_id="E5" subjects_affected="30" subjects_at_risk="792"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="60" subjects_at_risk="3714"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="1006"/>
                <counts group_id="E3" subjects_affected="47" subjects_at_risk="910"/>
                <counts group_id="E4" subjects_affected="34" subjects_at_risk="1375"/>
                <counts group_id="E5" subjects_affected="41" subjects_at_risk="792"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Heparin-induced thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3714"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="910"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1375"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="792"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3714"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="910"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1375"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="792"/>
              </event>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3714"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="910"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1375"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="792"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3714"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="910"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1375"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="792"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3714"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="910"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1375"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="792"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3714"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="910"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1375"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="792"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="3714"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="910"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1375"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="792"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3714"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="910"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1375"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="792"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3714"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="910"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1375"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="792"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3714"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="910"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1375"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="792"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3714"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1006"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="910"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1375"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="792"/>
              </event>
              <event>
                <sub_title>Cardiogenic shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3714"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="910"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1375"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="792"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3714"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="910"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1375"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="792"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3714"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="910"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1375"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="792"/>
              </event>
              <event>
                <sub_title>Pulseless electrical activity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3714"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="910"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1375"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="792"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3714"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="910"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1375"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="792"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Right-to-left cardiac shunt</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3714"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="910"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1375"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="792"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctival haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3714"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="910"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1375"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="792"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3714"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="910"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1375"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="792"/>
              </event>
              <event>
                <sub_title>Diverticular perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3714"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="910"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1375"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="792"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3714"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="910"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1375"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="792"/>
              </event>
              <event>
                <sub_title>Gastric ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3714"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="910"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1375"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="792"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3714"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="910"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1375"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="792"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3714"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="910"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1375"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="792"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3714"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="910"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1375"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="792"/>
              </event>
              <event>
                <sub_title>Lower gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3714"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="910"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1375"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="792"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3714"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="910"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1375"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="792"/>
              </event>
              <event>
                <sub_title>Retroperitoneal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3714"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="910"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1375"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="792"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3714"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="910"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1375"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="792"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Catheter site haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3714"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="910"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1375"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="792"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="3714"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1006"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="910"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="1375"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="792"/>
              </event>
              <event>
                <sub_title>Drug intolerance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3714"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="910"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1375"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="792"/>
              </event>
              <event>
                <sub_title>Multiple organ dysfunction syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3714"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="910"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1375"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="792"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3714"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="910"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1375"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="792"/>
              </event>
              <event>
                <sub_title>Peripheral swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3714"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="910"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1375"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="792"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3714"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="910"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1375"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="792"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3714"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="910"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1375"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="792"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3714"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="910"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1375"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="792"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3714"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1006"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="910"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1375"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="792"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3714"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="910"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1375"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="792"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3714"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="910"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1375"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="792"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3714"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="910"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1375"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="792"/>
              </event>
              <event>
                <sub_title>Lumbar vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3714"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="910"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1375"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="792"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3714"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="910"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1375"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="792"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3714"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="910"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1375"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="792"/>
              </event>
              <event>
                <sub_title>Subdural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3714"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="910"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1375"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="792"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood urine present</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3714"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="910"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1375"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="792"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3714"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="910"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1375"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="792"/>
              </event>
              <event>
                <sub_title>International normalised ratio increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3714"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="910"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1375"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="792"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3714"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="910"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1375"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="792"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Haemarthrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3714"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="910"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1375"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="792"/>
              </event>
              <event>
                <sub_title>Muscle haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3714"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="910"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1375"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="792"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Acute myeloid leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3714"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="910"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1375"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="792"/>
              </event>
              <event>
                <sub_title>Bronchial carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3714"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="910"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1375"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="792"/>
              </event>
              <event>
                <sub_title>Cervix carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3714"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="910"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1375"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="792"/>
              </event>
              <event>
                <sub_title>Diffuse large B-cell lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3714"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="910"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1375"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="792"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3714"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="910"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1375"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="792"/>
              </event>
              <event>
                <sub_title>Lung cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3714"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="910"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1375"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="792"/>
              </event>
              <event>
                <sub_title>Lung carcinoma cell type unspecified stage IV</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3714"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="910"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1375"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="792"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3714"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="910"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1375"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="792"/>
              </event>
              <event>
                <sub_title>Malignant neoplasm progression</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3714"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1006"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="910"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1375"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="792"/>
              </event>
              <event>
                <sub_title>Malignant peritoneal neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3714"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="910"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1375"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="792"/>
              </event>
              <event>
                <sub_title>Metastases to central nervous system</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3714"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="910"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1375"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="792"/>
              </event>
              <event>
                <sub_title>Metastatic renal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3714"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="910"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1375"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="792"/>
              </event>
              <event>
                <sub_title>Neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3714"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="910"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1375"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="792"/>
              </event>
              <event>
                <sub_title>Non-small cell lung cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3714"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="910"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1375"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="792"/>
              </event>
              <event>
                <sub_title>Oesophageal adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3714"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="910"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1375"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="792"/>
              </event>
              <event>
                <sub_title>Ovarian cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3714"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="910"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1375"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="792"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3714"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="910"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1375"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="792"/>
              </event>
              <event>
                <sub_title>Testicular cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3714"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="910"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1375"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="792"/>
              </event>
              <event>
                <sub_title>Uterine cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3714"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="910"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1375"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="792"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebellar haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3714"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="910"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1375"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="792"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3714"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="910"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1375"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="792"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3714"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="910"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1375"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="792"/>
              </event>
              <event>
                <sub_title>Coma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3714"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="910"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1375"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="792"/>
              </event>
              <event>
                <sub_title>Haemorrhage intracranial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3714"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="910"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1375"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="792"/>
              </event>
              <event>
                <sub_title>Haemorrhagic stroke</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3714"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="910"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1375"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="792"/>
              </event>
              <event>
                <sub_title>Hepatic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3714"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="910"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1375"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="792"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3714"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="910"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1375"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="792"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3714"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="910"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1375"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="792"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3714"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1006"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="910"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1375"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="792"/>
              </event>
              <event>
                <sub_title>Nephroptosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3714"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="910"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1375"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="792"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3714"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="910"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1375"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="792"/>
              </event>
              <event>
                <sub_title>Urinary bladder haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3714"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="910"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1375"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="792"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Menometrorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3714"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="910"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1375"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="792"/>
              </event>
              <event>
                <sub_title>Metrorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3714"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="910"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1375"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="792"/>
              </event>
              <event>
                <sub_title>Postmenopausal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3714"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="910"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1375"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="792"/>
              </event>
              <event>
                <sub_title>Uterine haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3714"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="910"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1375"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="792"/>
              </event>
              <event>
                <sub_title>Vaginal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3714"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="910"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1375"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="792"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3714"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="910"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1375"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="792"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3714"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="910"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1375"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="792"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3714"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="910"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1375"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="792"/>
              </event>
              <event>
                <sub_title>Chronic respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3714"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="910"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1375"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="792"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3714"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="910"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1375"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="792"/>
              </event>
              <event>
                <sub_title>Haemothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3714"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="910"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1375"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="792"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="3714"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="910"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="1375"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="792"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3714"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="910"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1375"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="792"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3714"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="910"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1375"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="792"/>
              </event>
              <event>
                <sub_title>Hypersensitivity vasculitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3714"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="910"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1375"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="792"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3714"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="910"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1375"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="792"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Abortion induced</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3714"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="910"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1375"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="792"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Arterial rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3714"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="910"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1375"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="792"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3714"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="910"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1375"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="792"/>
              </event>
              <event>
                <sub_title>Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3714"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="910"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1375"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="792"/>
              </event>
              <event>
                <sub_title>Internal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3714"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="910"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1375"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="792"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3714"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="910"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1375"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="792"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3714"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="910"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1375"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="792"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3714"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="910"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1375"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="792"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim, Call Center</name_or_title>
      <organization>Boehringer Ingelheim</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

